Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Is Wegovy the Same as Ozempic? The Biggest Difference

Is Wegovy the same as Ozempic? In the molecule, yes. Both contain semaglutide, made by Novo Nordisk. The biggest difference is who each brand is approved for. Every Ozempic use is for adults with type 2 diabetes. Wegovy's uses are weight management, heart risk in adults with established heart disease and obesity or overweight, and a liver disease called MASH, and none of them requires diabetes.

That split came from evidence, not branding. Each brand filed its own applications, and the key trials behind its uses enrolled different groups of people. Think of one key traveling on two passports, where every stamp is an approved use. This page lines up the stamps, then shows the main trials behind the heart, kidney, weight and liver uses, from the US labels and FDA records as of 20 November 2026.

On this page

What is the biggest difference between Wegovy and Ozempic?

The approved uses, and the people each use covers. Each shot has three uses on its US label. Diabetes decides which side a use falls on.

Every approved use of the Ozempic and Wegovy shots, from the US labels read 20 November 2026.
BrandApproved useWho it covers
OzempicBlood sugar controlAdults with type 2 diabetes
OzempicHeart riskAdults with type 2 diabetes and known heart disease
OzempicKidney riskAdults with both chronic kidney disease and type 2 diabetes
WegovyWeight managementAdults with obesity, some adults with overweight and a weight related medical problem, and children 12 and older with obesity
WegovyHeart riskAdults with established heart disease plus obesity or overweight
WegovyMASH, a liver diseaseAdults with moderate to advanced liver scarring, not cirrhosis (accelerated approval)

When we lined the two lists up, three things stood out.

  • Diabetes is the dividing line. All three Ozempic uses need type 2 diabetes. None of the three Wegovy uses does.
  • Only one kind of use shows up on both lists. That is heart risk. Blood sugar and kidneys belong to Ozempic alone. Weight and MASH belong to Wegovy alone.
  • Even the shared heart use covers different people. Ozempic's heart trial took only people with type 2 diabetes. Wegovy's heart trial took no one with diabetes. The two groups had no diabetes status in common.

Sources: Ozempic label, DailyMed, version 20; Wegovy label, DailyMed, version 19; Ozempic application NDA 209637, Drugs@FDA; Wegovy application NDA 215256, Drugs@FDA; SUSTAIN 6, NEJM 2016 (PMID 27633186); SELECT, NEJM 2023 (PMID 37952131)

What is the same about Wegovy and Ozempic?

The molecule. Both labels call the active ingredient semaglutide, a human GLP-1 receptor agonist. Both print one chemical formula, C187H291N45O59, and one molecular weight, 4113.58 g/mol. It matches 94 percent of the body's own GLP-1 hormone, so it fits the same lock: the GLP-1 receptor. How it was built to outlast the real hormone is on our page on what Wegovy is.

Even so, each label tells the story of its own uses. Ozempic's leads with blood sugar: semaglutide raises insulin and lowers glucagon when blood sugar is high. Wegovy's leads with appetite, since the brain has GLP-1 receptors in areas linked to how much we eat. Its brain evidence comes from animal studies. Oddly, the Ozempic label also notes that semaglutide reduces body weight. Yet Ozempic has no weight use. That use went to Wegovy, which earned it in weight trials.

Sources: Ozempic label, DailyMed, version 20; Wegovy label, DailyMed, version 19

How did one molecule end up with two approval lists?

Through two filings, about three and a half years apart. Drugs@FDA shows Ozempic was first approved on 5 December 2017, classed as a new molecular entity. That was the first US approval of semaglutide. Wegovy was approved on 4 June 2021 under its own application, filed as a new use for that same molecule. That is why both labels still read "Initial U.S. Approval: 2017".

Since then, each application has added uses of its own. Ozempic added its kidney use in January 2025. Wegovy added heart risk in March 2024 and MASH in August 2025. For the wider product comparison, our Wegovy vs Ozempic guide covers it.

Sources: Ozempic application NDA 209637, Drugs@FDA; Wegovy application NDA 215256, Drugs@FDA; Wegovy label, DailyMed, version 19; Ozempic label, DailyMed, version 20; FDA 2021 Wegovy approval release (Wayback copy)

Which trials sit behind the heart, kidney, weight and liver uses?

This is where the biggest difference comes from. Ozempic's outcome trials enrolled only people with type 2 diabetes. Wegovy's core weight trial and its heart trial enrolled people without it.

Selected outcome, weight and liver trials, from the published abstracts and the labels. The blood sugar trials are not listed here. Group averages, not predictions for one person.
BrandUseTrialWho was in itMain result
OzempicHeart riskSUSTAIN 63,297 people, all with type 2 diabetes and high cardiovascular riskHeart attack, stroke or cardiovascular death 6.6% vs 8.9% on placebo
OzempicKidney riskFLOW3,533 adults, all with type 2 diabetes plus kidney diseaseMajor kidney events 24% lower than placebo
WegovyWeightSTEP 11,961 adults with obesity or overweight, none with diabetesAverage weight fell 14.9%, against 2.4% on placebo
WegovyHeart riskSELECT17,604 adults aged 45 or older with heart disease and BMI 27 or more, none with diabetesHeart attack, stroke or cardiovascular death 6.5% vs 8.0% on placebo
WegovyLiver (MASH)ESSENCEAdults with MASH and moderate to advanced scarringStill running; the accelerated approval may depend on it

Placebo is the dummy comparison treatment in each trial. SUSTAIN 6, FLOW, STEP 1 and SELECT were all funded by Novo Nordisk.

Sources: SUSTAIN 6, NEJM 2016 (PMID 27633186); FLOW, NEJM 2024 (PMID 38785209); STEP 1, NEJM 2021 (PMID 33567185); SELECT, NEJM 2023 (PMID 37952131); ESSENCE trial record, NCT04822181

Why do the two heart uses cover different people?

Because they rest on different trials. The Ozempic heart use is for adults with type 2 diabetes and known heart disease. It aims to lower the risk of major events such as heart attack, stroke or death. Its trial, SUSTAIN 6, took 3,297 people with type 2 diabetes and a high risk of heart trouble. Those events came in 6.6 percent on semaglutide and 8.9 percent on placebo.

The Wegovy heart use came on 8 March 2024, and it does not need diabetes at all. It is for adults with established heart disease plus obesity or overweight. Its trial, SELECT, took 17,604 adults and left out anyone with type 1 or type 2 diabetes. There, the same kind of events came in 6.5 percent on semaglutide against 8.0 percent on placebo. One molecule, two heart trials, two groups that never overlapped on diabetes.

Sources: Ozempic label, DailyMed, version 20; SUSTAIN 6, NEJM 2016 (PMID 27633186); Wegovy label, DailyMed, version 19; SELECT, NEJM 2023 (PMID 37952131); FDA release on the heart use, March 2024

Which uses does only one brand have?

Ozempic alone has the kidney use. It is for adults living with chronic kidney disease as well as type 2 diabetes. The Medication Guide says it is meant to lower the risk of kidney disease worsening, kidney failure and death from cardiovascular disease. It was approved on 28 January 2025, based on FLOW. Among 3,533 adults with both conditions, major kidney disease events were 24 percent lower on semaglutide than on placebo. The trial stopped early at a planned check. The label says how it lowers kidney risk has not been established.

Wegovy alone has weight management. The shot is approved to bring down excess weight and keep it off long term. The core trial behind it, STEP 1, took 1,961 adults without diabetes who had obesity or overweight, for 68 weeks.

Wegovy alone also has MASH (metabolic dysfunction-associated steatohepatitis), a liver disease. That use came on 15 August 2025, for adults with moderate to advanced liver scarring but not cirrhosis. It was granted under accelerated approval. Whether it stays may depend on ESSENCE, a confirming trial that is still running. Picture a real license with one road test left to pass.

Sources: Ozempic label, DailyMed, version 20; FLOW, NEJM 2024 (PMID 38785209); Novo Nordisk release on the kidney approval, 28 January 2025; Wegovy label, DailyMed, version 19; STEP 1, NEJM 2021 (PMID 33567185); ESSENCE trial record, NCT04822181; Wegovy application NDA 215256, Drugs@FDA

Did diabetes change the weight results?

The numbers show a gap, not a cause. The FDA's 2021 summary of Wegovy's weight trials gave two figures. In adults with type 2 diabetes, weight lost beyond placebo was 6.2 percent. In adults without diabetes, it was 12.4 percent. Those came from separate trials, so the gap is a reported difference, not a tested cause. It is one more place where the diabetes line shows up in the record.

Sources: FDA 2021 Wegovy approval release (Wayback copy)

How current are these approval lists?

We re-read both labels on DailyMed on 20 November 2026. Both are prescription medicines approved in the US. The Ozempic label was version 20 (10 June 2026) and the Wegovy label was version 19 (30 June 2026). One caution: Drugs@FDA showed an Ozempic labeling change approved on 27 August 2026 that was not yet in the DailyMed copy. No new Ozempic use has been added since January 2025, but check the version number if you read the label yourself. Our checks follow our medical review policy.

Sources: DailyMed SPL index, Wegovy search; Ozempic label, DailyMed, version 20; Wegovy label, DailyMed, version 19; Ozempic application NDA 209637, Drugs@FDA

What else do people ask about Wegovy and Ozempic?

Is Wegovy the same drug as Ozempic?+

It is one molecule sold under two brand names. Both hold semaglutide from Novo Nordisk, and both labels print the same chemical formula. What sets them apart is what the FDA approved each brand for, and the trials and patient groups behind each approval.

What is the biggest difference between Wegovy and Ozempic?+

Who each one is approved for. All three Ozempic uses (blood sugar, heart risk and kidney risk) are limited to adults with type 2 diabetes. None of the three Wegovy shot uses (weight management, heart risk in adults with established heart disease and obesity or overweight, and MASH) requires diabetes.

Why does Ozempic have no weight management use?+

Every Ozempic use is for type 2 diabetes, and its heart and kidney trials enrolled only people with it. The Ozempic label does mention that semaglutide reduces body weight, but the weight use belongs to Wegovy, which earned it in its own weight trials, such as STEP 1 in adults without diabetes.

Why does Wegovy have a different name if it is the same molecule?+

Because it was filed on its own, for a new use. Ozempic was first approved in 2017 as a new molecular entity. Wegovy was approved in June 2021 under a separate application, as a new use of the same molecule, and it has added approvals of its own since then.

Why was weight loss smaller in the Wegovy diabetes trial?+

The FDA reported the figures without giving a reason: 6.2% beyond placebo in adults with type 2 diabetes, against 12.4% in adults without diabetes. These came from separate trials, so the gap is a reported difference, not a measured cause.

Sources: Ozempic label, DailyMed, version 20; Wegovy label, DailyMed, version 19; Ozempic application NDA 209637, Drugs@FDA; Wegovy application NDA 215256, Drugs@FDA; STEP 1, NEJM 2021 (PMID 33567185); FDA 2021 Wegovy approval release (Wayback copy)

So, is Wegovy the same as Ozempic?

Same molecule, different approvals. Ozempic's stamps are all for people with type 2 diabetes, and its heart and kidney trials enrolled only them. Wegovy's were earned for weight, heart risk in adults with established heart disease and obesity or overweight, and MASH, and its core weight trial, STEP 1, and its heart trial, SELECT, left people with diabetes out. That is the biggest difference between them.

Every Molecule Mechanics video is a short animation with its references listed underneath. This comparison draws on the Ozempic and Wegovy labels, Drugs@FDA, FDA and company releases and the trial abstracts as of 20 November 2026. For a different molecule with two targets, see semaglutide vs tirzepatide, and the research record for the molecule itself is in our semaglutide profile.

Found something that looks off? The corrections policy says how to flag it.

Sources: Ozempic label, DailyMed, version 20; Wegovy label, DailyMed, version 19; DailyMed SPL index, Wegovy search

This page compares two medicine labels and gives no advice. The facts are drawn from FDA labels and records, company releases and peer-reviewed trials, with sources at the end of each section. Nothing here suggests starting, stopping or switching a medicine. Please bring health questions to a licensed clinician.

Sources

  1. 1.Wegovy prescribing information and Medication Guide, Novo Nordisk, DailyMed SPL version 19 (published 30 June 2026), read 19 and 20 November 2026: contains semaglutide, a human GLP-1 receptor agonist; molecular formula C187H291N45O59 and molecular weight 4113.58 g/mol; backbone made by yeast fermentation; 94% sequence homology to human GLP-1; GLP-1 receptors in brain areas involved in appetite, and animal studies showing it reached brain regions that regulate food intake; initial US approval 2017; three uses of the shot (heart risk in adults with cardiovascular disease and obesity or overweight, weight management, MASH under accelerated approval); SELECT excluded people with type 1 or type 2 diabetes.
  2. 2.Ozempic prescribing information and Medication Guide, Novo Nordisk, DailyMed SPL version 20 (published 10 June 2026), read 19 and 20 November 2026: the same semaglutide wording, formula and yeast backbone; mechanism framed around insulin and glucagon in a glucose-dependent way; also notes semaglutide reduces body weight; three uses, all in adults with type 2 diabetes (blood sugar, heart risk with known heart disease, kidney risk with chronic kidney disease); no weight management use; mechanism of kidney risk reduction not established.
  3. 3.DailyMed search results for Wegovy labels, checked 20 November 2026: Novo Nordisk label version 19, published 30 June 2026. The Ozempic list read the same day shows version 20, published 10 June 2026.
  4. 4.Drugs@FDA (openFDA) record for NDA 209637, Ozempic, read 19 November 2026: original approval 5 December 2017, Type 1, New Molecular Entity; efficacy supplement approved 28 January 2025; a later labeling supplement approved 27 August 2026, not yet reflected in DailyMed version 20 when read.
  5. 5.Drugs@FDA (openFDA) record for NDA 215256, Wegovy, read 19 November 2026: original approval 4 June 2021, Type 10, new indication submitted as a distinct application; efficacy supplements approved 8 March 2024 and 15 August 2025.
  6. 6.FDA news release, 4 June 2021, archived by the Wayback Machine: Wegovy approved for chronic weight management; semaglutide was first approved as Ozempic for type 2 diabetes in 2017; in the trial in adults with type 2 diabetes, weight loss beyond placebo was 6.2%, against 12.4% in a trial in adults without diabetes.
  7. 7.FDA news release dated 8 March 2024: the agency added a Wegovy use for lowering cardiovascular death, heart attack and stroke risk in adults who have cardiovascular disease with obesity or overweight.
  8. 8.Novo Nordisk US news release, 28 January 2025: FDA approved Ozempic to lower kidney disease risk for adults who live with both type 2 diabetes and chronic kidney disease, based on the FLOW trial. Company source.
  9. 9.ClinicalTrials.gov, NCT04822181 (ESSENCE): semaglutide in MASH, status active, not recruiting, when checked for the video facts.
  10. 10.Marso SP and colleagues, SUSTAIN 6, NEJM 2016, PMID 27633186: 3,297 people with type 2 diabetes at high cardiovascular risk; heart attack, stroke or cardiovascular death in 6.6% on semaglutide vs 8.9% on placebo (hazard ratio 0.74). Novo Nordisk funded.
  11. 11.Perkovic V and colleagues, FLOW, NEJM 2024, PMID 38785209: 3,533 adults with type 2 diabetes and chronic kidney disease; major kidney disease events 24% lower with semaglutide than placebo; stopped early at a planned interim analysis. Novo Nordisk funded.
  12. 12.Lincoff AM and colleagues, SELECT, NEJM 2023, PMID 37952131: 17,604 adults aged 45 or older with cardiovascular disease, BMI 27 or more and no diabetes; heart attack, stroke or cardiovascular death in 6.5% vs 8.0% (hazard ratio 0.80). Novo Nordisk funded.
  13. 13.Wilding JPH and colleagues, STEP 1, NEJM 2021, PMID 33567185: 1,961 adults with obesity or overweight and no diabetes, 68 weeks; mean weight change minus 14.9% vs minus 2.4% on placebo. Novo Nordisk funded.